Pathogenesis and treatment of renal osteodystrophy
- PMID: 12944733
- DOI: 10.1159/000072552
Pathogenesis and treatment of renal osteodystrophy
Abstract
Renal osteodystrophy is the term used to describe the many different patterns of the skeletal abnormalities that occur in patients with chronic kidney disease. The main two conditions are osteitis fibrosa, characterized by high bone turnover, increased osteoclastic and osteoblastic activity, and high levels of circulating parathyroid hormone (PTH) and adynamic bone disease characterized by low bone turnover and low levels of circulating PTH. Retention of phosphorus, decreased levels of calcitriol in blood, decreased levels of serum ionized calcium, reduced numbers of vitamin D receptors and calcium sensors in the parathyroid gland, and skeletal resistance to the calcemic action of PTH play a major role in the development of renal osteodystrophy. This review will describe the current approach for the treatment of renal osteodystrophy.
Copyright 2003 S. Karger AG, Basel
Similar articles
-
[Renal osteodystrophy (3); its treatment in dialysis patients].Nephrologie. 2000;21(8):413-24. Nephrologie. 2000. PMID: 11213385 Review. French.
-
Review: Renal osteodystrophy--pathogenesis and treatment.Am J Med Sci. 1986 Apr;291(4):264-75. doi: 10.1097/00000441-198604000-00008. Am J Med Sci. 1986. PMID: 3518448 Review.
-
Renal osteodystrophy--pathogenesis and treatment.Am J Med Sci. 1985 Dec;290(6):234-45. doi: 10.1097/00000441-198512000-00003. Am J Med Sci. 1985. PMID: 3909812 Review.
-
[Role of vitamin D in the pathogenesis of renal osteodystrophy].Clin Calcium. 2004 Sep;14(9):15-20. Clin Calcium. 2004. PMID: 15577104 Review. Japanese.
-
Changing bone patterns with progression of chronic kidney disease.Kidney Int. 2016 Feb;89(2):289-302. doi: 10.1016/j.kint.2015.12.004. Kidney Int. 2016. PMID: 26806832 Review.
Cited by
-
Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal Disease.J Ren Nutr. 2015 Sep;25(5):433-9. doi: 10.1053/j.jrn.2015.03.001. Epub 2015 Apr 22. J Ren Nutr. 2015. PMID: 25912398 Free PMC article.
-
Metabolic bone disorders and the promise of marine osteoactive compounds.Cell Mol Life Sci. 2023 Dec 20;81(1):11. doi: 10.1007/s00018-023-05033-x. Cell Mol Life Sci. 2023. PMID: 38117357 Free PMC article. Review.
-
1α,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism.J Endocrinol Invest. 2008 Aug;31(8):711-7. doi: 10.1007/BF03346420. J Endocrinol Invest. 2008. PMID: 18852532
-
Phosphate-control adherence in hemodialysis patients: current perspectives.Patient Prefer Adherence. 2018 Jul 4;12:1175-1191. doi: 10.2147/PPA.S145648. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 30013329 Free PMC article. Review.
-
Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients.Am J Nephrol. 2010;32(5):403-13. doi: 10.1159/000319861. Epub 2010 Sep 3. Am J Nephrol. 2010. PMID: 20814200 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources